Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Recent Alzheimer's trials have recruited cognitively normal people at risk for Alzheimer's dementia. Due to the lack of clinical symptoms in normal population, conventional clinical outcome measures are not suitable for these early trials. While several groups are developing new composite cognitive tests that could serve as potential outcome measures by detecting subtle cognitive changes in normal people, there is a need for longitudinal brain imaging techniques that can correlate with temporal changes in these new tests and provide additional objective measures of neuropathological changes in brain. Positron emission tomography (PET) is a nuclear medicine imaging procedure based on the measurement of annihilation photons after positron emission from radiolabeled molecules that allow tracking of biological processes in body, including the brain. PET is a well-established in vivo imaging modality in Alzheimer's disease diagnosis and research due to its capability of detecting abnormalities in three major hallmarks of this disease. These include (1) amyloid beta plaques; (2) neurofibrillary tau tangles and (3) decrease in neuronal activity due to loss of nerve cell connection and death. While semiquantitative PET imaging techniques are commonly used to set discrete cut-points to stratify abnormal levels of amyloid accumulation and neurodegeneration, they are suboptimal for detecting subtle longitudinal changes. In this study, we have identified and discussed four critical barriers in conventional longitudinal PET imaging that may be particularly relevant for early Alzheimer's disease studies. These include within and across subject heterogeneity of AD-affected brain regions, PET intensity normalization, neuronal compensations in early disease stages and cerebrovascular amyloid deposition.
Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center.
Sepideh
S
Shokouhi
Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center.
Desmond
D
Campbell
Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center.
Aaron B
AB
Brill
Department of Psychiatry, Vanderbilt University Medical Center.
Harry E
HE
Gwirtsman
D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D049268:Positron-Emission Tomography; D039781:PubMed / Q000706:statistics & numerical data; D012189:Retrospective Studies; D013997:Time Factors; D016875:tau Proteins / Q000378:metabolism
D016229:Amyloid beta-Peptides; D016875:tau Proteins; D019788:Fluorodeoxyglucose F18
FDG; amyloid-PET; longitudinal PET; positron emission tomography; preclinical AD